Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) FCF Margin (2022 - 2025)

Historic FCF Margin for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to 286.85%.

  • Stoke Therapeutics' FCF Margin rose 1569200.0% to 286.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.47%, marking a year-over-year increase of 5313300.0%. This contributed to the annual value of 238.15% for FY2024, which is 7035700.0% up from last year.
  • Latest data reveals that Stoke Therapeutics reported FCF Margin of 286.85% as of Q3 2025, which was up 1569200.0% from 185.11% recorded in Q2 2025.
  • Stoke Therapeutics' 5-year FCF Margin high stood at 1055.0% for Q1 2022, and its period low was 897.18% during Q2 2023.
  • In the last 4 years, Stoke Therapeutics' FCF Margin had a median value of 443.77% in 2024 and averaged 372.74%.
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by -14801000bps in 2023, then surged by 6660100bps in 2025.
  • Over the past 4 years, Stoke Therapeutics' FCF Margin (Quarter) stood at 697.12% in 2022, then fell by -7bps to 745.11% in 2023, then skyrocketed by 86bps to 102.75% in 2024, then tumbled by -179bps to 286.85% in 2025.
  • Its last three reported values are 286.85% in Q3 2025, 185.11% for Q2 2025, and 83.04% during Q1 2025.